Skip to main content
SpringerLink
Log in

TNP-470

  • Chapter
Antiangiogenic Agents in Cancer Therapy

Part of the book series: Cancer Drug Discovery and Development ((CDD&D))

Abstract

Proliferation of endothelial cells is critical to the formation of new blood vessels. These cells, which form the innermost layer of the vasculature, are normally in the G0 phase of the cell cycle. They are able to respond to several different growth factors, and this response can result in neovascularization or angiogenesis. Angiogenesis is a normal physiologic component of growth, reproduction, and wound healing. It is also a pathogenic and critical component of tumor growth and metastasis, and it is this aspect of angiogenesis that the development of TNP-470 addresses.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 74.99
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Ingber, D., Fujita, T., Kishimoto, S., Sudo, K., Kanamaru, T., Brem, H., and Folkman, J. (1990) Synthetic analogues of fumagillin that inhibit angiogenesis and suppress tumor growth. Nature 348, 555–557.

    Article  PubMed  CAS  Google Scholar 

  2. Kusaka, M., Sudo, K., Fujita, T., Marui, S., Itoh, F., Ingber, D., and Folkman, J. (1991) Potent antiangiogenic action ofAGM-1470: comparison of the fumagillin parent. Biochem. Biophys. Res. Commun. 174, 1070–1076.

    Article  PubMed  CAS  Google Scholar 

  3. Kusaka, M., Sudo, K., Matsutani, E., Kozai, Y., Marui, S., Fujita, T., Ingber, D., and Folkman, J. (1994) Cytostatic inhibition of endothelial cell growth by the angiogenesis inhibitor TNP-470 (AGM-1470). Br. J. Cancer 69, 212–216.

    Article  PubMed  CAS  Google Scholar 

  4. Ito, Y., Iwamoto, Y., Oshima, N., and Sugioka, Y. (1996) Quantitative evaluation of the effects of an angiogenesis inhibitor, TNP-470, by an in vivo tumor angiogenesis assay using basement membrane extracts. Cancer J. (France) 9, 95–100.

    CAS  Google Scholar 

  5. Antoine, N., Greimers, R., De Roanne, C., Kusaka, M., Heinen E. Simar, L. J., and Castronovo, V. (1994) AGM-1470, a potent angiogenesis inhibitor, prevents the entry of normal but not transformed endothelial cells into the Gphase of the cell cycle. Cancer Res. 54, 2073–2076.

    PubMed  CAS  Google Scholar 

  6. Yanase, T., Tamura, M., Fujita, K., Kodama, S., and Tanaka, K. (1993) Inhibitory effect of angiogenesis inhibitor TNP-470 on tumor growth and metastasis of human cell lines in vitro and in vivo. Cancer Res. 53, 2566–2570.

    CAS  Google Scholar 

  7. Yamaoka, M., Yamamoto, T., Ikeyama, S., Sudo, K., and Fujita, T. (1993) Angiogenesis inhibitor TNP470 (AGM-1470) potentially inhibits the tumor growth of hormone-independent human breast and prostate carcinoma cell lines. Cancer Res. 53, 5233–5236.

    PubMed  CAS  Google Scholar 

  8. Takamiya, Y., Brem, H., Ojeifo, J., Mineta, T., and Martuza, R. L. (1994) AGM-1470 inhibits the growth of human glioblastoma cells in vitro and in vivo. Neurosurgery 34, 869–875.

    Article  CAS  Google Scholar 

  9. Antoine, N., Daukandt, M., Heinen, E., Simar, L. J., and Castronovo, V. (1996) In vitro and in vivo stimulation of murine immune system by AGM0–1470, a potent angiogenesis inhibitor. Am J. Pathol. 148, 393–398.

    CAS  Google Scholar 

  10. Antoine, N., Daukandt, M., Locigno, R., Heinen, E., Simar, L. J., and Castronovo, V. (1996) Potent antioinhibin AGM-1470 stimulates normal but not tumor lymphocytes. Tumor (Italy) 82, 27–30.

    CAS  Google Scholar 

  11. Isobe, N., Vozumi, T., Kuriso K., and Kawamoto, K. (1996) Antitumor effect of TNP-470 on glial tumors transplanted in rats. Anticancer Res. 16, 71–76.

    PubMed  CAS  Google Scholar 

  12. Yanase, T., Tamura, M., Fujita, K., Kodama, S., and Tanaka, K. (1993) Inhibitory effect of angiogenesis inhibitor TNP-470 on tumor growth and metastasis of human cell lines in vitro and in vivo. Cancer Res. 53, 2566–2570.

    CAS  Google Scholar 

  13. Schoof, D. D., Obando, J. A., Cusack, J. C., Jr., Goedegeburre, P. S., Brem, H., and Eberlein, T. J. (1993) Influence of angiogenesis inhibitor AGM-1470 on immune system status and tumor growth in vitro. Int. J. Cancer 55, 603–635.

    Google Scholar 

  14. Nagabuchi, E., Vander Kolk, W. E., Une, Y., and Ziegler, M. M. (1997) TNP-470 antiangiogenic therapy for advanced murine neuroblastoma. J. Ped Surg. 32, 287–293.

    Article  CAS  Google Scholar 

  15. Kamei, S., Okada, H., Inove, Y., Yoshioka, T., Ogawa, Y., and Toguchi, H. (1993) Antitumor effects of angiogenesis inhibitor TNP-470 in rabbits bearing VX-2 carcinoma by arterial administration of microspheres and oil solution. J. Pharmacol. Exp. Ther. 264, 469–474.

    PubMed  CAS  Google Scholar 

  16. Yanai, S., Okada, H., Misaki, M., Saito, K., Kuge, Y., Ogawa Y., and Toguchi, H. (1994) Antitumor activity of a medium-chain triglyceride solution of the angiogenesis inhibitor TNP-470 (AGM-1470) when administered via the hepatic artery to rats bearing Walker 256 carcinosarcoma in the liver. J. Pharmacol. Exp. Ther. 271, 1267–1273.

    PubMed  CAS  Google Scholar 

  17. Tanaka, Y., Kawamata, H., Fujimoto, K., and Oyasu, R. (1997) Angiogenesis inhibitor TNP-470 suppresses tumorigenesis in rat urinary bladder. J. Urol. 157, 683–688.

    Article  PubMed  CAS  Google Scholar 

  18. Yamaoka, M., Yamamoto, T., Masaki, T., Ikeyama, S., Sudo, K., and Fujita, K. (1993) Inhibition of tumor growth and metastasis of rodent tumor by the angiogenesis inhibitor O-(chloroacetyl-carbamoyl) funagillol. (TNP-470, AGM-1470). Cancer Res. 53, 4262–4267.

    PubMed  CAS  Google Scholar 

  19. Ahmed, M. H., Konno, H., Nahar, L., Tanaka, T., Naito, Y., Nakamora, S., and Baba, S. (1996) Angiogenesis inhibitor TNP-470 (AGM-1470) improves long term survival of rats with liver metastasis. J. Surg. Res. 64, 35–41.

    Article  PubMed  CAS  Google Scholar 

  20. Futami,H.Iseki,H.Egawa, S., Koyama, K., and Yamaguchi, K. (1996) Inhibition of lymphatic metastasis in a syngeneic rat fibrosarcoma model by an angiogenesis inhibitor (AGM-1470). Invasion Metastasis 16 73–82.

    Google Scholar 

  21. Kano, Y., Tamazaki, R., Shirai, Y., and Kakuta, H. (1996) Effects ofan injection ofanti-bFGF antibody (3H3) and angiogenesis inhibitor (TNP470) on mouse syngeneic solid tumor (NR-SI). Biotherapy, 10, 530–532.

    Google Scholar 

  22. Toi, M., Yamaoto, Y., Imazawa, T., Takanayagi, T., Akutsu, K., and Tominaga, T. (1993) Antitumor effect of the angiogenesis inhibitor AGM-1470 and its combination effect with tamoxifen in DMBA induced mammary tumors in rats. Int. J. Oncol. 3, 525–528.

    PubMed  CAS  Google Scholar 

  23. Toi, M., Yamamoto, Y., Imazawa, T., Takanayagi, T., Akutsu, K., and Tominaga, T. (1995) Combination effect of an angiogenesis inhibitor AGM-1470 with 5’ deoxy-5-fluorouridine, and with hormonal drugs in DMBA-induced rat mammary tumors. Oncol. Rep. 2, 793–798.

    PubMed  Google Scholar 

  24. Teicher, B. A., Emi, Y., Kakeji, Y., and Northey, D. (1996) TNP-470/minocycline/cytotoxic therapy: a systems approach to cancer therapy. Eur. J. Cancer 32A, 2461–2466.

    Article  Google Scholar 

  25. Kato, T., Sato, K., Kakinuma, H., and Matsuda, Y. (1994) Enhanced suppression of tumor growth by combination ofangiogenesis inhibitor O-(chloroacetyl-carbamoyl) fumagillol (TNP-470) and cytotoxic agents in mice. Cancer Res. 54, 5143–5147.

    PubMed  CAS  Google Scholar 

  26. Melesky, S. E., Zhang, L., Trock, B. J., Kharbanda, S., Liu, Y., Gottardis, M. M., Lippman, M. E., and Kern, E. G. (1996) Effects of AGM-1470 and pentosan polysulfate on tumorigenicity and metastasis of FGF-transfected MCF-7 cells. Br. J. Cancer 73, 1053–1062.

    Article  Google Scholar 

  27. Yano, T., Tanase, M., Watanabe, A., Sawada, H., Yamada, Y., Shino, Y., Nakano, H., and Ohnishi, T. (1995) Enhancement effect of an anti-angiogenic agent, TNP-470, on hyperthermia-induced growth suppression of human esophageal and gastric cancers transplantable to nude mice. Anticancer Res. 15, 1355–1358.

    PubMed  CAS  Google Scholar 

  28. Teicher, B. A., Holden, S. A., Dupuis, N. P., Kakeji, Y., Ikebe, M., Emi, Y., and Goff, D. (1995) Potentiation of cytotoxic therapies by TNP-470 and minoycline in mice bearing EMT-6 mammary carcinoma. Breast Cancer Res. Treat. 36, 227–236.

    Article  PubMed  CAS  Google Scholar 

  29. Teicher, B. A., Holden, S. A., Ara, G., Korbut, T., and Menon, K. (1996) Comparison of several antiangiogenic regimens alone and with cytotoxic therapies in Lewis lung carcinoma. Cancer Chemother. Pharmocol. 38, 169–177.

    Article  CAS  Google Scholar 

  30. Parangi, S., O’Reilly, M., Christofori, G., Holmgren, L., Grosfeld, J., Folkman, J., and Hanahan, D. (1996) Antiangiogenic therapy of transgenic mice impairs de novo tumor growth. Proc. Natl. Acad. Sci. USA 93, 2002–2007.

    Article  PubMed  CAS  Google Scholar 

  31. Teicher B. A., Dupuis, N. P., Robinson, M. F., Emi, Y., and Goff, D. A. (1995) Anti-angiogenesis treatment (TNP-470 minocycline) increases tissue levels ofanticancer drugs in mice bearing Lewis lung carcinoma. Oncol. Res. 7, 237–243.

    PubMed  CAS  Google Scholar 

  32. Devineni, D., Klein-Szanto, A., and Gallo, J. (1996) Uptake of temozolamide in a rat glioma model in the presence and absence of the angiogenesis inhibitor TNP-470. Cancer Res. 56, 1983–1987.

    PubMed  CAS  Google Scholar 

  33. Masuoka, S. (1996) Anti-tumor effects of an angiogenesis inhibitor, TNP-470 (AGM-1470) alone and in combination with cisplatinum, and changes in serum copper levels in liver cancer bearing rats. Hokkaido J. Med. Sci. 71, 69–80.

    Google Scholar 

  34. Dike, L. and Ingber, D. (1992) Inhibition of cell cycle progression in capillary endothelial cells by TNP470. Takeda Report N-5–113.

    Google Scholar 

  35. Abe, J., Zhou, W., Takuwa, N., Taguchi, J., Kurokawa, K., Kumada, M., and Takuwa, Y. (1994) A fumagillin derivative angiogenesis inhibitor, AGM-1470, inhibits activation ofcyclin-dependent kinases and phosporylation of retinoblastoma gene product but not protein tyrosyl phosphorylation or protooncogene expression in vascular endothelial cells. Cancer Res. 54, 3407–3412.

    PubMed  CAS  Google Scholar 

  36. Maier J. A. M., Delia, D., Thorpe, P. E., and Gasparini, G. (1997) In vitro inhibition of endothelial cell growth by the antiangiogenic drug AGM-1470 (TNP-470) and the anti-endoglin antibody TEC-11. AntiCancer Drugs 8, 238–244.

    CAS  Google Scholar 

  37. Budson, A. E., Ko, L., Brasel, C., and Brickoff, J. (1996) Angiogenesis inhibitor AGM-1470 selectively increases E-selectin. Biochem. Biophys. Res. Commun. 225, 141–145.

    Article  PubMed  CAS  Google Scholar 

  38. Koyama, H., Nishizawa, Y., Hosoi, M., Fukumoto, S., Kogawa, K., Shioi, A., and Morii, H. (1996) Fumagillin analog TNP-470 inhibits DNA synthesis of vascular smooth muscle cells stimulated by platelet-derived growth factor and insulin-like growth factor-1. Circ. Res. 79, 757–764.

    Article  PubMed  CAS  Google Scholar 

  39. Kano, Y., Yamazaki, R., Shirai, Y., and Kakuta, H. (1996) Effects of an injection of anti-bFGF antibody (3H3) and angiogenesis inhibitor (TNP-470) on mouse syngeneic solid tumor (NR-SI). Biotherapy (Japanese) 10, 530–532.

    Google Scholar 

  40. Fujimoto, J., Hori, M., Ichigo, S., Hirose, R., Sakaguchi, H., and Tamaya, T. (1997) Plausible novel therapeutic strategy of uterine endometrial cancer with reduction of basic fibroblast growth factor secretion by progestin and O-(chloroacety-carbamoyl) fumagillol (TNP-470, AGM-1470). CancerLett. 113, 187–194.

    CAS  Google Scholar 

  41. Kondo, M. (1996) Inhibitory effect of angiogenesis inhibitor TNP-470 in proliferation and liver metastasis of colon-26 cells in vitro and in vivo. Nippon Daicho-Koumonbio Koishi (Japanese) 49, 101–111.

    Article  Google Scholar 

  42. Sin, Y., Meng, L., Wang M. Q. W., Wen, J. J., Bornmann, W. G., and Crews, C. M. (1997) The antiangiogenic fumagillin covalently binds and inhibits the methionine aminopeptidase, MetAP-2. Proc. Natl. Acad. Sci. USA 94, 6099–6103.

    Article  PubMed  CAS  Google Scholar 

  43. Daha, B., Chakrabarti, D., Roy, A., and Gupta, N. K. (1988) Roles of a 67-kDa polypeptide in reversal of protein synthesis inhibition in heme-defiiciant reticulocyte lysate. Proc. Natl. Acad. Sci. USA 85, 3324–3328.

    Article  Google Scholar 

  44. Wu, S., Rehemtulla, A., Gupta, N. K., and Kaufmann, R. J. (1996) Eukaryotic translation initiation factor-2-associated 67-kDa glycoprotein partially reverses protein synthesis inhibition by activated double-stranded RNA-dependent protein kinase in intact cells. Biochemistry 35, 8275–8280.

    Article  PubMed  CAS  Google Scholar 

  45. Peseckis, S. M., Drichaite, I., and Resh, M. D. (1993) Iodinated fatty acids as probes for myristate processing and function. J. Biol. Chem. 268, 5107–5114.

    PubMed  CAS  Google Scholar 

  46. Bachmair A. Finely, D., and Varshavsky, A. (1986) In vivo half-life of a protein is a function of its aminoterminal residue. Science 234, 179–186.

    Google Scholar 

  47. Dezube, B. J., Von Roenn, J. H., Holden-Wiltse, J., Cheung, T. W., Remick, S. C., Cooley, T. P., et al. (1997) Fumagillin analog (TNP-470) in the treatment of Kaposi’s sarcoma: A Phase I AIDS Clinical Trial Group Study. J. Clin. Oncol. submitted.

    Google Scholar 

  48. Levy, T., Kudelka, A., Vershraegen, C. F., Edwards, C. L., Freedman, R. S., Kaplan, A., et al. (1996) A Phase I study of TNP-470 administered to patients with advanced squamous cell cancer of the cervix. Proc. Am. Assoc. Cancer Res. 37, 166A (abstract)

    Google Scholar 

  49. Kudelka, A. P., Levy, T., Verschraegen, C. F., Edwards, C. L., Piamsomboon, S., Termrungruanglert, W., et al. (1997) A Phase I study of TNP-470 administered to patients with advanced squamous cell cancer of the cervix. Clin. Cancer Res. submitted.

    Google Scholar 

  50. Bhargava, P., Marshall, J., Rizvi, N., Dahut, W., Yoe, J., Figueira, M., et al. (1997) Study of TNP-470 in patients with advanced cancer. Am. Assoc. Cancer Res 38, 1489A.

    Google Scholar 

  51. Holmgren, L., O’Reilly, M. S., and Folkman, J. (1997) Dormancy of micrometastases: balanced proliferation and apoptosis in the presence of angiogenesis suppression. Nature Med. 1, 149–153.

    Google Scholar 

Download references

Authors
  1. Deborah M. Milkowski
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Rachelle A. Weiss
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Lilly Research Laboratories, Lilly Corporate Center, Indianapolis, IN, USA

    Beverly A. Teicher

Rights and permissions

Reprints and permissions

Copyright information

© 1999 Springer Science+Business Media New York

About this chapter

Cite this chapter

Milkowski, D.M., Weiss, R.A. (1999). TNP-470. In: Teicher, B.A. (eds) Antiangiogenic Agents in Cancer Therapy. Cancer Drug Discovery and Development. Humana Press, Totowa, NJ. https://doi.org/10.1007/978-1-59259-453-5_22

Download citation

  • DOI: https://doi.org/10.1007/978-1-59259-453-5_22

  • Publisher Name: Humana Press, Totowa, NJ

  • Print ISBN: 978-1-4757-4518-4

  • Online ISBN: 978-1-59259-453-5

  • eBook Packages: Springer Book Archive

Publish with us

Policies and ethics

Search

Navigation